对基于D-Pinitol的治疗方法的新见解:高酸化与胰岛素抵抗之间的联系
Dina Medina-Vera1, Antonio Jesús López-Gambero2, Juan Antonio Navarro3
1Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, UGC Salud Mental; Facultad de Ciencias, Universidad de Málaga; CIBER Enfermedades Cardiovasculares (CIBERCV), Hospital Universitario Virgen de la Victoria, UGC del Corazón, Málaga, Spain.
Neural regeneration research
|July 25, 2023
概括
本综述探讨了阿尔茨海默病,蛋白和内醇之间的联系. 了解大脑的胰岛素抵抗可能会揭示阿尔茨海默病治疗的新治疗点.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 是一种神经退行性疾病,其特征是大脑粉样蛋白积累.
- 蛋白酸化和聚合是AD的关键致病机制.
- 大脑的胰岛素耐药性越来越被认为是陶过酸化的一个重要因素.
研究的目的:
- 审查阿尔茨海默病,病理和内醇之间的复杂关系.
- 探索伊诺醇作为潜在的胰岛素敏感剂,用于AD治疗.
- 为了确定修改AD进展的新型治疗点.
主要方法:
- 现有科学文献的叙述性审查.
- 分析AD,陶酸化和胰岛素信号传递之间的相互作用.
- 在阿尔茨海默病的背景下,评估因诺醇作为胰岛素敏感剂的作用.
主要成果:
- 该综述强调大脑的胰岛素耐药性是阿尔茨海默病中陶过酸化的关键媒介.
- 伊诺醇显示出作为胰岛素敏感剂的潜力,提供治疗途径.
- 阿尔茨海默病,和内醇的相互联系为开发新的疾病修饰剂提供了一个框架.
结论:
- 通过内醇准大脑的胰岛素抵抗可能为阿尔茨海默病的干预提供了一个有希望的策略.
- 对AD-tau-inositol轴的进一步研究可能会导致有效的治疗方法.
- 本综述巩固了当前的知识,以指导未来的AD药物开发.
相关概念视频
Insulin: The Receptor and Signaling Pathways
1.3K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.3K
Dipeptidyl Peptidase 4 Inhibitors
212
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
212
PI3K/mTOR/AKT Signaling Pathway
3.7K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.7K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.3K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.3K
Insulin: Biosynthesis, Chemistry, and Preparation
432
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
432
Glucagon-like Receptor Agonists
358
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
358


